Palomar Holdings, Inc. (NASDAQ:PLMR – Get Free Report) President Jon Christianson sold 522 shares of Palomar stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $128.04, for a total transaction of $66,836.88. Following the completion of the sale, the president directly owned 65,919 shares in the company, valued at approximately $8,440,268.76. This represents a 0.79% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Jon Christianson also recently made the following trade(s):
- On Saturday, January 31st, Jon Christianson sold 515 shares of Palomar stock. The shares were sold at an average price of $121.75, for a total transaction of $62,701.25.
- On Saturday, January 31st, Jon Christianson sold 515 shares of Palomar stock. The stock was sold at an average price of $121.75, for a total transaction of $62,701.25.
- On Thursday, January 29th, Jon Christianson sold 1,158 shares of Palomar stock. The shares were sold at an average price of $122.04, for a total value of $141,322.32.
- On Thursday, January 29th, Jon Christianson sold 1,158 shares of Palomar stock. The shares were sold at an average price of $122.04, for a total value of $141,322.32.
- On Wednesday, January 28th, Jon Christianson sold 1,991 shares of Palomar stock. The stock was sold at an average price of $119.88, for a total value of $238,681.08.
- On Tuesday, December 23rd, Jon Christianson sold 1,691 shares of Palomar stock. The shares were sold at an average price of $139.50, for a total value of $235,894.50.
Palomar Price Performance
Shares of NASDAQ PLMR opened at $120.61 on Friday. The stock has a market capitalization of $3.20 billion, a PE ratio of 16.80 and a beta of 0.44. Palomar Holdings, Inc. has a one year low of $107.75 and a one year high of $175.85. The business’s fifty day moving average price is $129.40 and its 200-day moving average price is $123.17.
Analyst Ratings Changes
A number of research firms have recently commented on PLMR. Weiss Ratings raised Palomar from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, January 14th. Keefe, Bruyette & Woods raised their target price on Palomar from $170.00 to $171.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 6th. Wall Street Zen raised Palomar from a “hold” rating to a “buy” rating in a report on Saturday. JPMorgan Chase & Co. upped their price target on Palomar from $145.00 to $155.00 and gave the company an “overweight” rating in a research report on Wednesday, January 7th. Finally, Evercore began coverage on shares of Palomar in a research report on Monday, February 9th. They issued an “outperform” rating and a $150.00 price objective for the company. Seven investment analysts have rated the stock with a Buy rating, According to MarketBeat, Palomar presently has a consensus rating of “Buy” and an average target price of $162.17.
Check Out Our Latest Stock Report on Palomar
Hedge Funds Weigh In On Palomar
A number of institutional investors have recently added to or reduced their stakes in the business. Janus Henderson Group PLC boosted its position in shares of Palomar by 250.1% during the 4th quarter. Janus Henderson Group PLC now owns 795,625 shares of the company’s stock valued at $107,237,000 after acquiring an additional 568,360 shares during the last quarter. Invesco Ltd. raised its stake in Palomar by 234.1% in the second quarter. Invesco Ltd. now owns 798,361 shares of the company’s stock valued at $123,147,000 after purchasing an additional 559,383 shares in the last quarter. Alliancebernstein L.P. lifted its position in Palomar by 290.2% during the second quarter. Alliancebernstein L.P. now owns 497,080 shares of the company’s stock valued at $76,675,000 after purchasing an additional 369,697 shares during the last quarter. Westfield Capital Management Co. LP grew its stake in Palomar by 81.0% in the 3rd quarter. Westfield Capital Management Co. LP now owns 738,528 shares of the company’s stock worth $86,223,000 after buying an additional 330,592 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. grew its stake in Palomar by 72.1% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 785,165 shares of the company’s stock worth $105,809,000 after buying an additional 328,993 shares in the last quarter. 90.25% of the stock is currently owned by institutional investors.
Palomar News Roundup
Here are the key news stories impacting Palomar this week:
- Positive Sentiment: Quarterly beat: Palomar reported $2.24 EPS vs. $2.06 expected and reported revenue of ~$492.6M (up 62.7% YoY), showing solid margin and growth that support upside to earnings forecasts. Quarterly Results
- Positive Sentiment: Analyst upgrade momentum: Wall Street Zen upgraded PLMR to a “Buy” and several other firms (JPMorgan, Evercore, Keefe Bruyette & Woods, Weiss) recently raised ratings/targets, supporting a consensus target well above current levels and providing bullish catalyst. Wall Street Zen Upgrade
- Neutral Sentiment: High institutional ownership (~90%): heavy institutional concentration shrinks the effective float — that can amplify price moves when funds rotate but also means retail flows matter less. Ownership Details
- Neutral Sentiment: Technical setup: the shares are trading around and below the 50‑day (~$129.40) and near the 200‑day (~$123), reflecting short‑term weakness that may trigger selling until buyers step in. Technicals
- Negative Sentiment: Insider selling: multiple insiders sold shares on Feb. 18 — CFO T. Christopher Uchida (783 shares), President Jon Christianson (522 shares) and director Jonathan Knutzen (281 shares). While sizes are small relative to total holdings, clustered insider sales have likely contributed to investor caution today. Insider Selling
Palomar Company Profile
Palomar Holdings, Inc (NASDAQ: PLMR) is a specialty insurance holding company focused on providing medical stop-loss coverage and related administrative services to self-funded employer health plans in the United States. The firm operates through two primary business segments—Medical Stop-Loss and Specialty Program Management—to deliver tailored risk protection and comprehensive program administration.
In its Medical Stop-Loss segment, Palomar underwrites excess and aggregate stop-loss policies designed to shield self-insured employers from catastrophic medical claims that exceed pre-determined retention levels.
Featured Articles
- Five stocks we like better than Palomar
- ~$1.5T SpaceX IPO: Pre-IPO Opportunity
- Gold $5,000: The 2026 Gold & Silver Summit is LIVE March 4
- How a Family Trust May Be Able To Help Preserve Your Wealth
- This makes me furious
- Elon Musk: This Could Turn $100 into $100,000
Receive News & Ratings for Palomar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palomar and related companies with MarketBeat.com's FREE daily email newsletter.
